The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
Quinapril: A Double-Blind, Placebo-Controlled Trial in Essential Hypertension
Quinapril HCl is a novel , nonsulf hydryl angiotensin-converting en zyme ( ACE ) inhibitor . The Study Group evaluated its efficacy ( 20 , 40 , 80 mg daily with forced dose titration determination at trough blood pres sure ) once daily versus twice daily versus placebo , as well as its tolera bility and safety , in 270 patients with mild to moderate essential hyperten sion ( WHO Stages I and II , sitting diastolic blood pressure [ DPB ] ≥95 mm Hg ) , for twelve weeks . Reduc tions in DBP of up to 13 mm Hg were obtained , and in full dosage more than 65 % of patients achieved a re duction in DBP of 10 mm Hg or more from baseline or reduced their DBP to 90 mm Hg or less  . Quinapril was well tolerated , and reported adverse effects were scarcely more frequent than in the placebo group . Once daily doses of quinapril were as safe and effective as twice-daily doses . Quina pril is likely to exhibit good therapeu tic utility in the management of essential hypertension
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .